Saturday 17 October 2026
Export DCOY’s income statement to Excel — free account
Decoy Therapeutics Inc
DCOY Healthcare Biotechnology
In the quarter to June 2026, revenue fell 84.6%, EPS grew 94.5% and free cash flow fell 212.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow DCOY
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(139.55%) | (338.31%) | (661.72%) | (827.77%) | |
| (100.53%) | (177.82%) | (242.20%) | (278.04%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(118.71%) | (213.70%) | (338.76%) | (336.66%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(110.55) | (55.68) | (12.28) | (16.81) | |
Free Cash Flow |
(4.43) | (5.40) | (6.53) | (8.94) | |
Capital Expenditures |
— | (0.57) | — | (0.62) | |
| Other line items | |||||
Cash ROIC |
(48.94%) | (32.54%) | (55.86%) | (70.91%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 519.79% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 198.09% | |
Share Based Compensation of Revenue |
— | — | — | 0.00% | |
Operating CF/Net income |
0.89 | 0.39 | 0.50 | 0.58 | |
Depreciation/Fixed assets |
0.00 | 0.18 | 0.34 | 0.06 | |
Capex/Depreciation |
0.00 | (79.71) | 0.00 | (25.09) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 3.89 | |
Operating CF per Share |
(110.55) | (49.76) | (12.28) | (15.65) | |
Capex per Share |
0.00 | (5.92) | 0.00 | (1.16) | |
Capex to Sales |
— | 0.00 | — | 0.30 |
Columns are period end dates